entertainment -WSS

entertainment

author：entertainment 2025-10-01 10:59:07 - browse：43832

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： FTC falls short on scrutinizing hospital mergers, study says

WSS

Close Medicare's dangerous gaps in addiction treatment coverage

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Element Biosciences CEO lays out genome sequencing strategy

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Dogs on Prozac: What pet anti

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Wikipedia

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Medical leaders decry Supreme Court decision on affirmative action

FTC falls short on scrutinizing hospital mergers, study says

Sports medicine is finally prioritizing gender equality

Finland to offer bird flu vaccine to select groups of people, a possible global first

Moonlake's readout produced a cash windfall. Risks remain

Structure Therapeutics oral GLP

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

An outdated Medicare rule harms dementia patients with anxiety

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Diversity in clinical trials starts with building trust, experts say

focus

Element Biosciences CEO lays out genome sequencing strategy

Elevance PBM president out as customers face prescription chaos

How CO2 helps viruses stay alive longer in the air

Illumina board agrees to spin off Grail, as divestment plans proceed

Exact Sciences stock tumbles despite strong cancer detection sales

Cancer researcher Catriona Jamieson is sending tumors into space

hotspot

entertainment

hotspot

hotspot